Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Meningococcal Immunisation Clinical Trial

Official title:

Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04825223
• Other study ID #: VAN00002
• Secondary ID: U1111-1244-0377
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: March 29, 2021
• Est. completion date: May 5, 2026

Study information

• Verified date: September 2023
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

• To describe the safety profile of the SP MenB vaccine formulations and the 2 licensed MenB comparator vaccines in healthy adults, adolescents, toddlers and infants, when administered alone (Stages 1-4) or concomitantly with MenQuadfiTM (MenACYW conjugate vaccine) (for Stages 2-4 only), and with age-appropriated routine pediatric vaccines (for Stages 3-4 only)

1. To describe the safety profile of the SP MenB vaccine formulations, Bexsero Vaccine and Trumenba Vaccine in healthy adults, and adolescents;

2. To describe the safety profile of the SP MenB vaccine formulations and Bexsero Vaccine in toddlers and infants;

3. To describe the safety profile of the SP MenB vaccine formulations,

• when administered alone

• when administered with MenQuadfiTM (MenACYW conjugate vaccine)

• when administered with routine infant immunizations

• To describe the immune response to the SP MenB vaccine formulations and the 2 licensed MenB comparator vaccines after the last dose of primary vaccination in healthy adults, adolescents, toddlers and infants, when administered alone, or concomitantly with MenQuadfi Vaccine or other routine vaccines, as measured by the serum bactericidal assay using human complement (hSBA) in the primary panel of MenB strains by Stage, by age group and by vaccine schedule

Secondary Objective:

• To describe the immune response to the SP MenB vaccine formulations and the 2 licensed MenB comparator vaccines at each timepoint in healthy adults, adolescents, toddlers and infants, when administered alone or concomitantly with MenQuadfi Vaccine or other routine vaccines as measured by hSBA in the primary panel of MenB strains by Stage by age group and by vaccine schedule

• To describe the immune response (breadth of coverage) in the secondary panel of MenB strains in participants (adults and adolescents) in Stage 1 and 2 after the last dose of the primary series in each group

• To describe the persistence of immune response following primary series at D366, and immune response 1 month after a booster dose of the SP MenB vaccine given 1-year post-dose 1 (at D366) in a subset of adults and adolescents in Stage 2 who received SP MenB vaccine formulations, Bexsero Vaccine or Trumenba Vaccine as measured by hSBA in the primary panel of MenB strains by age group

• To describe the immune response against meningococcal serogroups A, C, W and Y measured with hSBA in participants from each agegroup receiving MenQuadfi Vaccine

Description:

Study duration per participant will be approximately: 7 months for Stage 1 participants, 12 to 18.5 months for Stage 2 participants, 12 months for Stage 3 participants and 18 months for Stage 4 participants

In each vaccine group at each age group (Stage 1, 3 and 4 only), the first 5 participants enrolled (sentinels) will be assessed via early safety data review (ESDR) as a cohort for the evaluation of biological safety and overall safety profile for D01-D08 post dose 1. The safety data collected will be reviewed before proceeding with recruitment of remaining participants in each study group. Enrollment of remaining participants randomized to each group will be based on the outcome of the safety assessments of the sentinels: only a positive review outcome will allow the enrollment of the sentinel cohort of the respective lower age group.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 576
• Est. completion date: May 5, 2026
• Est. primary completion date: May 5, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 42 Days to 50 Years

Eligibility

Inclusion criteria :

-For US: Aged 10 to 25 years on the day of inclusion ("10-25 years" means from the day of the 10th birthday to the day before the 26th birthday) For EU: Aged 42 to 89 days or 12 to 18 months or 10 to 50 years on the day of inclusion ("42 to 89 days" means from 42 days after birth to the 89th day after birth; "12-18 months" means from the12th month after birth to the day before the 19th month after birth; "10-50 years" means from the day of the 10th birthday to the day before the 51st birthday Participants or participant and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures Covered by health insurance (applicable depending on local regulations) Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and judgement of the Investigator

For adults: A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

• Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile OR

• Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first study intervention administration until at least 4 weeks after the last study intervention administration.

A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) the day of any dose of study intervention

For adolescents: A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

• Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be pre-menarche OR

• Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first study intervention administration until at least 4 weeks after the last study intervention administration A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) the day of any dose of study intervention -For infants: Born at full term of pregnancy (=37 weeks) and with a birth weight =2.5 kg or born after a gestation period of 27 through 36 weeks and medically stable as assessed by the investigator, based on the following definition: "Medically stable" refers to the condition of premature infants who do not require significant medical support or ongoing management for debilitating disease and who have demonstrated a clinical course of sustained recovery by the time they receive the first dose of study intervention - - -

Exclusion criteria:

-Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months or since birth for infants and toddlers; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months or since birth for infants and toddlers) History of any Neisseria meningitidis infection, confirmed either clinically, serologically, or microbiologically At high risk for meningococcal infection during the trial (specifically, but not limited to, participants with persistent complement deficiency, with anatomic or functional asplenia, or participants travelling to countries with high endemic or epidemic disease) Individuals with active tuberculosis Known systemic hypersensitivity to latex or to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances For adults and adolescents: Self-report of thrombocytopenia, contraindicating intra-muscular (IM) vaccination * For infants and toddlers: Laboratory-confirmed thrombocytopenia, or known thrombocytopenia, as reported by the parent/legally acceptable representative contraindicating intramuscular vaccination Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination For infants and toddlers: History of intussusception Receipt of any vaccine in the 4 weeks (28 days) preceding the first trial vaccination or planned receipt of any vaccine 4 weeks before to 4 weeks after each trial vaccination or study visit with collection of blood for immunogenicity assessments, except for influenza vaccination, which may be received at least 2 weeks before or 2 weeks after any study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines Previous vaccination against meningococcal B disease with either the study vaccines or another licensed or investigational vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroup B) For infants and toddlers: Previous vaccination against meningococcal disease with either the study vaccines or any other licensed or investigational vaccine containing serogroups A, C, W, Y; or meningococcal serogroup B Receipt of immune globulins, blood or blood-derived products in the past 3 months or since birth for infants and toddlers Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first immunogenicity blood draw For infants: Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis A, measles, mumps, rubella, varicella; and Haemophilus influenzae type b, Streptococcus pneumoniae, and /or rotavirus infection or disease, and receipt of more than 1 previous dose of hepatitis B vaccine Participation at the time of study enrollment (or in the 4 weeks preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion Moderate or severe acute illness/infection (according to the investigator's judgment), febrile illness (temperature = 38.0°C or = 100.4°F). A prospective participant should not be enrolled in the study until the condition has resolved or the febrile event has subsided History of Guillain-Barré syndrome History of any neurologic disorders, including any seizures and progressive neurologic disorders Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily For adults and adolescents: Identified as an investigator or employee of the investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed study For infants and toddlers: Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study For adults and adolescents: Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Meningococcal Immunisation

Intervention

Drug:
• Multicomponent Meningococcal B Vaccine
Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
• Meningococcal Group B Vaccine MenB
Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
• Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)
Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
• Placebo
Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
• Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine
Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular

Locations

Country	Name	City	State
Puerto Rico	Investigational Site Number :6300003	Ponce
Puerto Rico	Investigational Site Number :6300001	San Juan
United States	Kentucky Pediatric Research Inc-Site Number:8400009	Bardstown	Kentucky
United States	Progressive Clinical Research-Site Number:8400028	Bountiful	Utah
United States	Hope Clinical Research, Inc.-Site Number:8400001	Canoga Park	California
United States	WCCT Global, Inc.-Site Number:8400015	Cypress	California
United States	AMR El Dorado-Site Number:8400018	El Dorado	Kansas
United States	SIMEDHealth, LLC-Site Number:8400045	Gainesville	Florida
United States	The Research Center of the Upstate-Site Number:8400008	Greenville	South Carolina
United States	Lakeview Clinical Research-Site Number:8400029	Guntersville	Alabama
United States	MD Clinical-Site Number:8400027	Hallandale Beach	Florida
United States	Brengle Family Medicine-Site Number:8400044	Indianapolis	Indiana
United States	AMR Lexington-Site Number:8400002	Lexington	Kentucky
United States	Michael W. Simon, MD, PSC-Site Number:8400026	Lexington	Kentucky
United States	Advanced Clinical Research - Magic View-Site Number:8400024	Meridian	Idaho
United States	Prime Global Research, Inc.-Site Number:8400043	New York	New York
United States	California Research Foundation-Site Number:8400005	San Diego	California
United States	Moore Clinical Research Inc-Site Number:8400030	Tampa	Florida
United States	PAS Research, LLC-Site Number:8400032	Tampa	Florida
United States	Pediatric Clinical Trials Tullahoma-Site Number:8400020	Tullahoma	Tennessee
United States	Alliance for Multispecialty Research LLC-Site Number:8400013	Wichita	Kansas
United States	AMR Wichita East-Site Number:8400012	Wichita	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi Pasteur, a Sanofi Company

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with immediate adverse events (AEs)	Unsolicited systemic AEs that occur within 30 minutes after vaccination	Within 30 minutes after vaccination
Primary	Number of participants with solicited injection site reactions or systemic reactions	Adverse reactions pre-listed in the protocol and case report form (CRF) Injection site reactions: pain, erythema and swelling (or tenderness, erythema and swelling for infants and toddlers) Systemic reactions: fever, headache, malaise, myalgia (or fever, vomiting, crying abnormal, drowsiness, appetite lost, irritability for infants and toddlers)	Within 7 days after vaccination
Primary	Number of participants with unsolicited AEs	AEs that do not fulfill the conditions of solicited reactions	Within 30 days after vaccination
Primary	Number of participants with serious adverse events (SAEs)	SAEs reported throughout the study, including adverse events of special interest (AESI)s	Up to 6 months after last vaccination
Primary	Number of participants with medically attended adverse events (MAAE)s	AEs with a new onset or a worsening of a condition that prompts the participant or participant's parent/guardian to seek unplanned medical advice at a physician's office or Emergency Department	Up to 6 months after last vaccination
Primary	Number of participants with out-of-range biological test results	Out-of-range biological test results occurring in the sentinel cohorts of each age group	From baseline (pre-vaccination) up to Day 07 (post-vaccination)
Primary	Antibody titers in the primary panel of MenB strains before primary vaccination	Antibody titers measured by serum bactericidal assay using human complement (hSBA)	Day 01 (pre-vaccination)
Primary	Antibody titers in the primary panel of MenB strains after primary vaccination	Antibody titers measured by hSBA	Day 30 (post-vaccination)
Secondary	Antibody titers in the primary panel of MenB strains after each vaccination	Antibody titers measured by hSBA	Day 01, Day 31, Day 61, Day 91, Day 181, Day 211, Day 366 and Day 396
Secondary	Antibody titers in the secondary panel of MenB strains (stage 1 and 2 only)	Antibody titers measured by hSBA	Day 01 (pre-vaccination) and Day 30 (post-vaccination)
Secondary	Antibody titers in the primary panel of MenB strains (stage 2 only)	Antibody titers measured by hSBA	Day 366 (pre-vaccination) and Day 396 (post-vaccination)
Secondary	Antibody titers against each of Men A, C, W, and Y strains	Antibody titers measured by hSBA in participants receiving MenQuadfi vaccine	Day 01 (pre-vaccination) and Day 30 (post-vaccination)